This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Kite Pharma, Inc.
Kite Pharma, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of cell therapy innovation. Founded in 2009, Kite has made significant strides in the development of chimeric antigen receptor (CAR) T-cell therapies, primarily targeting cancer treatment. With a strong operational presence across North America and Europe, the company focuses on harnessing the power of the immune system to combat malignancies. Kite's flagship products, including Yescarta, are distinguished by their ability to provide personalised treatment options for patients with certain types of blood cancers. The company has achieved notable recognition within the industry, establishing itself as a pioneer in the field of oncology. With a commitment to advancing cell therapy, Kite Pharma continues to shape the future of cancer treatment, positioning itself as a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Kite Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kite Pharma, Inc.'s score of 58 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kite Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Gilead Sciences, Inc., and therefore, any climate commitments or emissions data may be cascaded from its parent organisation. Kite Pharma has not outlined any specific reduction targets or initiatives in its own documentation. However, it is important to note that it inherits sustainability and climate-related initiatives from Gilead Sciences, Inc. This includes participation in various climate frameworks such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are associated with Gilead Sciences at the first cascade level. As a subsidiary, Kite Pharma's climate commitments and performance metrics are likely aligned with Gilead's broader sustainability goals, although specific details regarding emissions reductions or targets have not been disclosed. The absence of direct emissions data highlights the need for further transparency in reporting and commitment to climate action within the biopharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 36,813,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kite Pharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
